**Supplementary appendix 1**

**e-Table 1. Adverse events (AE) for 102 multiple sclerosis patients treated with Rituximab**

|  |  |
| --- | --- |
| **Adverse Events** | **No. of patients (%)** |
| **Infections (all the infections)** | 64 (62.74%) |
| Gastrointestinal infections (Colitis) | 13 (12.74%) |
| Respiratory tract infections (Pneumonia, Bronchitis, Sinusitis, Rhinitis, Tonsillitis) | 28 (27.45%) |
| Urinary infections (Cystitis, Candida) | 13 (12.74%) |
| Herpes virus related infections | 16 (15.69%) |
| Other infections | 4 (3.92%) |
| **Other AE (Headache, Fatigue, Hypertension, Skin disorder, Fractures)** | 46 (45.10%) |
| **Pregnancy** | 9 (8.82%) |

**e-Table 2. List of the Serious adverse events (SAE) for 102 multiple sclerosis patients treated with Rituximab**

|  |  |
| --- | --- |
| **Serious Adverse Events** | **No. of patients (%)** |
| **Breast cancer** | 1 |
| **Fractures** | 7 |
| **Infections (all the infections)** | 5 |
| **Mediastinal neoplasm** | 1 |
| **Unknown neoplasm requiring radiotherapy** | 1 |
| **Suicide attempt** | 1 |